Inhibition of Ca
Animals
Benzeneacetamides
/ pharmacology
Calcium Channel Blockers
/ pharmacology
Calcium Channels, T-Type
/ genetics
Colon
/ drug effects
Dextran Sulfate
Disease Models, Animal
Ethosuximide
/ pharmacology
Ganglia, Spinal
/ drug effects
Heterocyclic Compounds, 2-Ring
/ pharmacology
Inflammation
/ chemically induced
Inflammatory Bowel Diseases
/ physiopathology
Interleukin-6
/ immunology
Irritable Bowel Syndrome
/ physiopathology
Male
Mice, Inbred C57BL
Mice, Knockout
Nociceptors
/ drug effects
Pyridines
/ pharmacology
Sulfonamides
/ pharmacology
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
13
07
2018
revised:
13
12
2018
accepted:
02
01
2019
pubmed:
5
2
2019
medline:
25
4
2020
entrez:
5
2
2019
Statut:
ppublish
Résumé
Abdominal pain associated with low-grade inflammation is frequently encountered in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) during remission. Current treatments are not very effective and new therapeutic approaches are needed. The role of Ca Low doses of dextran sulfate sodium (DSS; 0.5%) were chronically administered to C57BL/6j mice in drinking water. Their inflammatory state was assessed by systemic and local measures of IL-6, myeloperoxidase, and lipocalin-2 using elisa. Colonic sensitivity was evaluated by the visceromotor responses to colorectal distension. Functional involvement of Ca DSS induced low-grade inflammation associated with CHS in mice. Genetic or pharmacological inhibition of Ca These results suggest that ethosuximide represents a promising drug reposition strategy and that inhibition of Ca
Sections du résumé
BACKGROUND AND PURPOSE
Abdominal pain associated with low-grade inflammation is frequently encountered in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) during remission. Current treatments are not very effective and new therapeutic approaches are needed. The role of Ca
EXPERIMENTAL APPROACH
Low doses of dextran sulfate sodium (DSS; 0.5%) were chronically administered to C57BL/6j mice in drinking water. Their inflammatory state was assessed by systemic and local measures of IL-6, myeloperoxidase, and lipocalin-2 using elisa. Colonic sensitivity was evaluated by the visceromotor responses to colorectal distension. Functional involvement of Ca
KEY RESULTS
DSS induced low-grade inflammation associated with CHS in mice. Genetic or pharmacological inhibition of Ca
CONCLUSIONS AND IMPLICATIONS
These results suggest that ethosuximide represents a promising drug reposition strategy and that inhibition of Ca
Identifiants
pubmed: 30714145
doi: 10.1111/bph.14608
pmc: PMC6433640
doi:
Substances chimiques
2-(4-cyclopropylphenyl)-N-(1-(5-((2,2,2-trifluoroethyl)oxo)pyridin-2-yl)ethyl)acetamide
0
4-chloro-2-fluoro-N-(2-fluorophenyl)-5-(hexahydropyrrolo(1,2-a)pyrazin-2(1H)-ylcarbonyl)benzenesulfonamide
0
Benzeneacetamides
0
Cacna1h protein, mouse
0
Calcium Channel Blockers
0
Calcium Channels, T-Type
0
Heterocyclic Compounds, 2-Ring
0
Interleukin-6
0
Pyridines
0
Sulfonamides
0
interleukin-6, mouse
0
Ethosuximide
5SEH9X1D1D
Dextran Sulfate
9042-14-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
950-963Informations de copyright
© 2019 The British Pharmacological Society.
Références
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):205-17
pubmed: 25732745
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Gut. 2019 Apr;68(4):633-644
pubmed: 29483303
Am J Gastroenterol. 2010 Aug;105(8):1796-8
pubmed: 20686466
Neurogastroenterol Motil. 2010 Jun;22(6):626-e174
pubmed: 20403099
Med J Aust. 2017 Sep 2;207(7):309-315
pubmed: 28954618
Clin Microbiol Rev. 2002 Jan;15(1):79-94
pubmed: 11781268
Br J Pharmacol. 2019 Apr;176(7):950-963
pubmed: 30714145
PLoS One. 2012;7(9):e44328
pubmed: 22957064
Gut. 2017 May;66(5):966-974
pubmed: 28232472
Neuron. 2014 Sep 3;83(5):1144-58
pubmed: 25189210
World J Gastroenterol. 2016 Aug 21;22(31):7111-23
pubmed: 27610021
Curr Protoc Immunol. 2014 Feb 04;104:15.25.1-15.25.14
pubmed: 24510619
Cell Rep. 2015 Jan 20;10(3):370-382
pubmed: 25600872
Br J Pharmacol. 2012 Oct;167(4):917-28
pubmed: 22646666
Dig Dis Sci. 2006 Mar;51(3):440-5
pubmed: 16619394
J Gastroenterol. 2011 Apr;46(4):421-31
pubmed: 21331765
PLoS Biol. 2015 May 20;13(5):e1002151
pubmed: 25992600
Gut. 2014 May;63(5):744-52
pubmed: 23878165
Mol Pain. 2015 Mar 14;11:12
pubmed: 25889575
Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4
pubmed: 22426087
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Am J Physiol Gastrointest Liver Physiol. 2016 Oct 1;311(4):G581-G586
pubmed: 27514480
Br J Pharmacol. 2017 Dec;174 Suppl 1:S160-S194
pubmed: 29055033
J Manag Care Pharm. 2013 Nov-Dec;19(9):755-64
pubmed: 24156644
Pain. 2013 Feb;154(2):283-93
pubmed: 23257507
Neuroscience. 2011 May 5;181:257-64
pubmed: 21354272
Brain Res. 1988 May 31;450(1-2):153-69
pubmed: 3401708
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
Br J Pharmacol. 2015 Jul;172(14):3461-71
pubmed: 26114403
J Neurosci Res. 2015 Feb;93(2):361-9
pubmed: 25267397
Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G215-27
pubmed: 19407218
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11268-73
pubmed: 21690417
Neurogastroenterol Motil. 2016 Nov;28(11):1632-1640
pubmed: 27196538
Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359
pubmed: 29055034
Front Neurosci. 2011 Feb 22;5:16
pubmed: 21390285
CNS Drug Rev. 2007 Summer;13(2):224-39
pubmed: 17627674
BMJ Open. 2017 Jul 18;7(7):e015380
pubmed: 28720615
N Engl J Med. 2009 Nov 19;361(21):2066-78
pubmed: 19923578
Sci Transl Med. 2017 Sep 27;9(409):eaam6072
pubmed: 28954930
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):189-199
pubmed: 28404134
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
World J Gastroenterol. 2010 Jul 7;16(25):3168-77
pubmed: 20593502
Am J Gastroenterol. 2012 Oct;107(10):1474-82
pubmed: 22929759
Pain. 2005 Jan;113(1-2):27-36
pubmed: 15621361
PLoS One. 2016 Jun 22;11(6):e0156666
pubmed: 27332879
Pain. 2008 Oct 15;139(2):243-7
pubmed: 18814968
Am J Gastroenterol. 1999 May;94(5):1320-6
pubmed: 10235213
Science. 2003 Nov 21;302(5649):1416-8
pubmed: 14631046
Lancet Gastroenterol Hepatol. 2017 Feb;2(2):112-122
pubmed: 28403981
JAMA. 2015 Mar 3;313(9):949-58
pubmed: 25734736
EMBO J. 2005 Jan 26;24(2):315-24
pubmed: 15616581
J Neurosci. 2012 Jul 4;32(27):9374-82
pubmed: 22764245
Br J Pharmacol. 2018 Jun;175(12):2375-2383
pubmed: 28608534
N Engl J Med. 2002 Aug 8;347(6):417-29
pubmed: 12167685
Neuroscience. 2012 Oct 25;223:77-91
pubmed: 22858598
Gut. 2007 Feb;56(2):203-9
pubmed: 17005763
World J Gastroenterol. 2018 Sep 7;24(33):3681-3694
pubmed: 30197475
Gastroenterology. 2016 Feb 18;:
pubmed: 27144627
J Physiol. 2006 Dec 1;577(Pt 2):513-23
pubmed: 17008378
Biochem Pharmacol. 2014 Jun 15;89(4):536-44
pubmed: 24726441
PLoS One. 2014 Apr 04;9(4):e91467
pubmed: 24705276
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986
J Physiol. 2011 Apr 1;589(Pt 7):1691-706
pubmed: 21320883
J Pharmacol Sci. 2012;119(3):293-6
pubmed: 22785020
Pain. 1983 Jun;16(2):109-10
pubmed: 6877845